


Q&A Session at the Financial Results Briefing for the Six Months Ended for the FYE March 2026

Date of Financial Results Briefing: November 12, 2025



TSE Prime Market Securities code: 7600

Q1	Regarding the remaining supply chain risks in U.S. knee joint manufacturing, when do you anticipate the supply chain will normalize?
A	Currently, BKS Primary (first-time replacement product) and BKS Revision Knee (Replace Again product) face supply chain risks. ①BKS Primary Knee Joint Regarding BKS Primary, improvements to manufacturing issues are progressing, and we expect to see a resolution within the year. ②Revision Knee product BKS Revision Knee BKS Revision Knee continues to experience manufacturing issues within the supply chain. Based on current projections, we anticipate this situation will persist until the first quarter of 2026. This product has a high unit price and generates significant sales, so it has been reflected in the full-year sales forecast for the FYE ending March 2026.
Q2	Could you share details about the new product scheduled for launch in the U.S. during the 2H, to the extent possible?
A	The new product scheduled for launch in the U.S. in the 2H will be in the Hip joint field.



3

Regarding forward-looking statements

- Statements regarding the future, such as business performance forecasts, contained in this material are based on information currently available to the Company and certain assumptions that the Company deems to be reasonable, and the Company is committed to realizing them. Not.
- Actual results may differ significantly due to various factors.